NAV
₹18.8601
as of 30 Sept 2026
Expense Ratio
1.51%
Lumpsum returns (CAGR)
- 1Y
- +21.77%
- 3Y
- +20.55%
- 5Y
- —
- Since Inception
- +21.88%
SIP returns (XIRR)
- 1Y
- +28.44%
- 3Y
- +15.90%
- 5Y
- —
- Since Inception
- +16.56%
Performance Comparison
Sectoral allocation
as of 31 Aug 2026Each sector links to the mutual funds most exposed to it.
Thinking about quant Healthcare Fund · Direct · Growth?
Talk to our AMFI-registered team — free, no pressure. We'll help you see if this fund fits your goals.
Compare with Similar Funds
Fund Details
Available transactions
Portfolio holdings
portfolio shared with quant Healthcare Fund - Growth Option - Regular Plan
- 1Glaxosmithkline Pharmaceuticals Ltd10.58%
- 2Zydus Lifesciences Limited9.30%
- 3Pfizer Ltd8.83%
- 4Alivus Life Sciences8.08%
- 5Concord Biotech Limited7.03%
- 6Sms Pharmaceuticals Limited6.71%
- 7Ipca Laboratories Ltd6.22%
- 8Zydus Wellness Ltd5.64%
- 9Aurobindo Pharma Limited5.18%
- 10Strides Pharma Science Ltd2.45%
What this fund does
quant Healthcare Fund · Direct · Growth invests in stocks from a specific sector or theme, offering concentrated exposure to a particular area of the economy. These funds carry sector-specific risks but can deliver significant returns when the underlying sector performs well.
About This Fund
quant Healthcare Fund · Direct · Growth is a Sectoral / Thematic mutual fund offered by quant Mutual Fund. The fund has been operational for over 3 years. The current expense ratio is 1.51%.